{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T04:52:00Z","timestamp":1787028720569,"version":"build-2736575974"},"reference-count":44,"publisher":"MDPI AG","issue":"6","license":[{"start":{"date-parts":[[2024,5,31]],"date-time":"2024-05-31T00:00:00Z","timestamp":1717113600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82172326"],"award-info":[{"award-number":["82172326"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["22QA1407700"],"award-info":[{"award-number":["22QA1407700"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Shanghai Rising-Star Program","award":["82172326"],"award-info":[{"award-number":["82172326"]}]},{"name":"Shanghai Rising-Star Program","award":["22QA1407700"],"award-info":[{"award-number":["22QA1407700"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JoF"],"abstract":"<jats:p>The efficacy of different echinocandins is assessed by evaluating the in vitro activity of a novel antifungal, rezafungin, against invasive fungal isolates in comparison with anidulafungin and caspofungin. Using the broth microdilution (BMD) method, the susceptibility of 1000 clinical Candida isolates (including 400 C. albicans, 200 C. glabrata, 200 C. parapsilosis, 150 C. tropicalis and 50 C. krusei) and 150 Aspergillus isolates (100 A. fumigatus and 50 A. flavus) from the Eastern China Invasive Fungi Infection Group (ECIFIG) was tested for the antifungals including anidulafungin, rezafungin, caspofungin and fluconazole. The echinocandins showed strong activity against C. albicans that was maintained against fluconazole-resistant isolates. The GM MIC (geometric mean minimum inhibitory concentration) value of rezafungin was found to be comparable to that of anidulafungin or caspofungin against the five tested common Candida species. C. tropicalis exhibited higher resistance rates (about 8.67\u201340.67% in different antifungals) than the other four Candida species. Through the sequencing of FKS genes, we searched for mutations in echinocandin-resistant C. tropicalis isolates and found that all displayed alterations in FKS1 S654P. The determined MEC (minimal effective concentration) values against A. fumigatus and A. flavus for rezafungin (0.116 \u03bcg\/mL, 0.110 \u03bcg\/mL) are comparable to those of caspofungin (0.122 \u03bcg\/mL, 0.142 \u03bcg\/mL) but higher than for anidulafungin (0.064 \u03bcg\/mL, 0.059 \u03bcg\/mL). Thus, the in vitro activity of rezafungin appears comparable to anidulafungin and caspofungin against most common Candida and Aspergillus species. Rezafungin showed higher susceptibility rates against C. glabrata. Rezafungin indicates its potent activity for potential clinical application.<\/jats:p>","DOI":"10.3390\/jof10060397","type":"journal-article","created":{"date-parts":[[2024,5,31]],"date-time":"2024-05-31T06:35:32Z","timestamp":1717137332000},"page":"397","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["In Vitro Activitiy of Rezafungin in Comparison with Anidulafungin and Caspofungin against Invasive Fungal Isolates (2017 to 2022) in China"],"prefix":"10.3390","volume":"10","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9362-2789","authenticated-orcid":false,"given":"Simin","family":"Yang","sequence":"first","affiliation":[{"name":"Department of Laboratory Medicine, Shanghai East Hospital, Tongji University School of Medicine, 1800 Yuntai Road, Pudong New District, Shanghai 200123, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-6510-6582","authenticated-orcid":false,"given":"Feifei","family":"Wan","sequence":"additional","affiliation":[{"name":"Department of Laboratory Medicine, Shanghai East Hospital, Tongji University School of Medicine, 1800 Yuntai Road, Pudong New District, Shanghai 200123, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Min","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Laboratory Medicine, Shanghai East Hospital, Tongji University School of Medicine, 1800 Yuntai Road, Pudong New District, Shanghai 200123, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4437-1631","authenticated-orcid":false,"given":"Huiping","family":"Lin","sequence":"additional","affiliation":[{"name":"Department of Laboratory Medicine, Shanghai East Hospital, Tongji University School of Medicine, 1800 Yuntai Road, Pudong New District, Shanghai 200123, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liang","family":"Hu","sequence":"additional","affiliation":[{"name":"Department of Laboratory Medicine, Shanghai East Hospital, Tongji University School of Medicine, 1800 Yuntai Road, Pudong New District, Shanghai 200123, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ziyi","family":"Zhou","sequence":"additional","affiliation":[{"name":"Department of Laboratory Medicine, Shanghai East Hospital, Tongji University School of Medicine, 1800 Yuntai Road, Pudong New District, Shanghai 200123, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dongjiang","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Laboratory Medicine, Shanghai East Hospital, Tongji University School of Medicine, 1800 Yuntai Road, Pudong New District, Shanghai 200123, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aiping","family":"Zhou","sequence":"additional","affiliation":[{"name":"Department of Laboratory Medicine, Shanghai East Hospital, Tongji University School of Medicine, 1800 Yuntai Road, Pudong New District, Shanghai 200123, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lijun","family":"Ni","sequence":"additional","affiliation":[{"name":"Department of Laboratory Medicine, Shanghai East Hospital, Tongji University School of Medicine, 1800 Yuntai Road, Pudong New District, Shanghai 200123, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jian","family":"Guo","sequence":"additional","affiliation":[{"name":"Department of Laboratory Medicine, Shanghai East Hospital, Tongji University School of Medicine, 1800 Yuntai Road, Pudong New District, Shanghai 200123, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenjuan","family":"Wu","sequence":"additional","affiliation":[{"name":"Department of Laboratory Medicine, Shanghai East Hospital, Tongji University School of Medicine, 1800 Yuntai Road, Pudong New District, Shanghai 200123, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2024,5,31]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1055\/s-0040-1701215","article-title":"Invasive Candidiasis","volume":"41","year":"2020","journal-title":"Semin. Respir. Crit. Care Med."},{"key":"ref_2","doi-asserted-by":"crossref","unstructured":"Du, H., Bing, J., Hu, T., Ennis, C.L., Nobile, C.J., and Huang, G. (2020). Candida auris: Epidemiology, biology, antifungal resistance, and virulence. PLoS Pathog., 16.","DOI":"10.1371\/journal.ppat.1008921"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"18026","DOI":"10.1038\/nrdp.2018.26","article-title":"Invasive candidiasis","volume":"4","author":"Pappas","year":"2018","journal-title":"Nat. Rev. Dis. Primers"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1093\/cid\/civ933","article-title":"Clinical Practice Guideline for the Management of Candidiasis: 2016 Update by the Infectious Diseases Society of America","volume":"62","author":"Pappas","year":"2016","journal-title":"Clin. Infect. Dis."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"1366","DOI":"10.1128\/JCM.02117-09","article-title":"Results from the ARTEMIS DISK Global Antifungal Surveillance Study, 1997 to 2007: A 10.5-year analysis of susceptibilities of Candida Species to fluconazole and voriconazole as determined by CLSI standardized disk diffusion","volume":"48","author":"Pfaller","year":"2010","journal-title":"J. Clin. Microbiol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"e00577-18","DOI":"10.1128\/JCM.00577-18","article-title":"Five-Year National Surveillance of Invasive Candidiasis: Species Distribution and Azole Susceptibility from the China Hospital Invasive Fungal Surveillance Net (CHIF-NET) Study","volume":"56","author":"Xiao","year":"2018","journal-title":"J. Clin. Microbiol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"5352","DOI":"10.1038\/s41467-022-32249-5","article-title":"The importance of antimicrobial resistance in medical mycology","volume":"13","author":"Gow","year":"2022","journal-title":"Nat. Commun."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1016\/j.idc.2021.03.003","article-title":"Resistance to Antifungal Drugs","volume":"35","author":"Kontoyiannis","year":"2021","journal-title":"Infect. Dis. Clin. N. Am."},{"key":"ref_9","first-page":"358","article-title":"Effects of cytochrome b5 on cytochrome P-450-catalyzed reactions. Studies with manganese-substituted cytochrome b5","volume":"12","author":"Morgan","year":"1984","journal-title":"Drug Metab. Dispos."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"27","DOI":"10.2217\/fmb-2020-0217","article-title":"Rezafungin: A novel antifungal for the treatment of invasive candidiasis","volume":"16","author":"Ham","year":"2021","journal-title":"Future Microbiol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1016\/j.cmi.2018.01.002","article-title":"Diagnosis and management of Aspergillus diseases: Executive summary of the 2017 ESCMID-ECMM-ERS guideline","volume":"24","author":"Ullmann","year":"2018","journal-title":"Clin. Microbiol. Infect."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.2217\/fmb.13.90","article-title":"Caspofungin benefit on phagocytes from patients with renal dysfunction infected with multidrug-resistant Candida glabrata","volume":"8","author":"Banche","year":"2013","journal-title":"Future Microbiol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"792","DOI":"10.1016\/j.cmi.2019.03.028","article-title":"Resistance of Candida to azoles and echinocandins worldwide","volume":"25","author":"Pristov","year":"2019","journal-title":"Clin. Microbiol. Infect."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1016\/j.diagmicrobio.2016.02.009","article-title":"Antifungal susceptibility patterns of a global collection of fungal isolates: Results of the SENTRY Antifungal Surveillance Program (2013)","volume":"85","author":"Castanheira","year":"2016","journal-title":"Diagn. Microbiol. Infect. Dis."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"1724","DOI":"10.1093\/cid\/cit136","article-title":"Increasing echinocandin resistance in Candida glabrata: Clinical failure correlates with presence of FKS mutations and elevated minimum inhibitory concentrations","volume":"56","author":"Alexander","year":"2013","journal-title":"Clin. Infect. Dis."},{"key":"ref_16","doi-asserted-by":"crossref","unstructured":"Zhao, Y., and Perlin, D.S. (2020). Review of the Novel Echinocandin Antifungal Rezafungin: Animal Studies and Clinical Data. J. Fungi, 6.","DOI":"10.3390\/jof6040192"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/S0140-6736(22)02324-8","article-title":"Rezafungin versus caspofungin for treatment of Candidaemia and invasive candidiasis (ReSTORE): A multicentre, double-blind, double-dummy, randomised phase 3 trial","volume":"401","author":"Thompson","year":"2023","journal-title":"Lancet"},{"key":"ref_18","unstructured":"The U.S. Food and Drug Administration (2006, February 17). Drugs@FDA: FDA-Approved Drug [EB\/OL], Available online: https:\/\/www.accessdata.fda.gov\/scripts\/cder\/daf\/index.cfm?event=overview.process&ApplNo=021948."},{"key":"ref_19","unstructured":"US Food and Drug Administration (2024, May 03). Rezzayo Prescribing Information, Available online: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2023\/217417s000lbl.pdf."},{"key":"ref_20","unstructured":"(2017). Reference Method for Broth Dilution Antifungal Susceptibility Testing of Yeasts (Standard No. CLSI Standard M27)."},{"key":"ref_21","unstructured":"(2017). Reference Method for Broth Dilution Antifungal Susceptibility Testing of Filamentous Fungi (Standard No. CLSI Standard M38)."},{"key":"ref_22","unstructured":"(2022). Performance Standards for Antifungal Susceptibility Testing of Yeasts (Standard No. CLSI Document M27M44S)."},{"key":"ref_23","doi-asserted-by":"crossref","unstructured":"Carvalhaes, C.G., Klauer, A.L., Rhomberg, P.R., Pfaller, M.A., and Castanheira, M. (2022). Evaluation of Rezafungin Provisional CLSI Clinical Breakpoints and Epidemiological Cutoff Values Tested against a Worldwide Collection of Contemporaneous Invasive Fungal Isolates (2019 to 2020). J. Clin. Microbiol., 60.","DOI":"10.1128\/jcm.02449-21"},{"key":"ref_24","unstructured":"(2022). Epidemiological Cutoff Values for Antifungal Susceptibility Testing (Standard No. CLSI Document M57S)."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1016\/j.idc.2021.03.007","article-title":"Candidemia and Invasive Candidiasis","volume":"35","author":"McCarty","year":"2021","journal-title":"Infect. Dis. Clin. N. Am."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"3390","DOI":"10.1021\/acs.chemrev.0c00199","article-title":"Antifungal Drug Resistance: Molecular Mechanisms in Candida albicans and Beyond","volume":"121","author":"Lee","year":"2021","journal-title":"Chem. Rev."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"e00111-18","DOI":"10.1128\/CMR.00111-18","article-title":"Candida parapsilosis: From Genes to the Bedside","volume":"32","author":"Nosek","year":"2019","journal-title":"Clin. Microbiol. Rev."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"e0158423","DOI":"10.1128\/aac.01584-23","article-title":"Outcomes by Candida spp. in the ReSTORE Phase 3 trial of rezafungin versus caspofungin for candidemia and\/or invasive candidiasis","volume":"68","author":"Locke","year":"2024","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"3505","DOI":"10.1093\/jac\/dkz390","article-title":"In vitro activity of rezafungin against common and rare Candida species and Saccharomyces cerevisiae","volume":"74","author":"Locke","year":"2019","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"e01627-16","DOI":"10.1128\/AAC.01627-16","article-title":"Safety and Pharmacokinetics of CD101 IV, a Novel Echinocandin, in Healthy Adults","volume":"61","author":"Sandison","year":"2017","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"6872","DOI":"10.1128\/AAC.00701-16","article-title":"Preclinical Evaluation of the Stability, Safety, and Efficacy of CD101, a Novel Echinocandin","volume":"60","author":"Ong","year":"2016","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"e02438-19","DOI":"10.1128\/AAC.02438-19","article-title":"Rezafungin In Vitro Activity against Contemporary Nordic Clinical Candida Isolates and Candida auris Determined by the EUCAST Reference Method","volume":"64","author":"Helleberg","year":"2020","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_33","unstructured":"(2019). Development of In Vitro Susceptibility Testing Criteria and Quality Control Parameters (Standard No. CLSI Document M23)."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1016\/j.cmi.2018.02.021","article-title":"Multicentre determination of rezafungin (CD101) susceptibility of Candida species by the EUCAST method","volume":"24","author":"Arendrup","year":"2018","journal-title":"Clin. Microbiol. Infect."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"5836","DOI":"10.1128\/AAC.01519-13","article-title":"Interlaboratory variability of Caspofungin MICs for Candida spp. Using CLSI and EUCAST methods: Should the clinical laboratory be testing this agent?","volume":"57","author":"Arendrup","year":"2013","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1128\/JCM.02659-15","article-title":"Effects of Treated versus Untreated Polystyrene on Caspofungin In Vitro Activity against Candida Species","volume":"54","author":"Fothergill","year":"2016","journal-title":"J. Clin. Microbiol."},{"key":"ref_37","doi-asserted-by":"crossref","unstructured":"Wang, Y., Fan, X., Wang, H., Kudinha, T., Mei, Y.-N., Ni, F., Pan, Y.-H., Gao, L.-M., Xu, H., and Kong, H.-S. (2021). Continual Decline in Azole Susceptibility Rates in Candida tropicalis over a 9-Year Period in China. Front. Microbiol., 12.","DOI":"10.3389\/fmicb.2021.702839"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"302.e5","DOI":"10.1016\/j.cmi.2021.10.004","article-title":"Azole and echinocandin resistance mechanisms and genotyping of Candida tropicalis in Japan: Cross-boundary dissemination and animal-human transmission of C. tropicalis infection","volume":"28","author":"Khalifa","year":"2022","journal-title":"Clin. Microbiol. Infect."},{"key":"ref_39","doi-asserted-by":"crossref","unstructured":"Sharifi, M., Badiee, P., Abastabar, M., Morovati, H., Haghani, I., Noorbakhsh, M., and Mohammadi, R. (2023). A 3-year study of Candida infections among patients with malignancy: Etiologic agents and antifungal susceptibility profile. Front. Cell. Infect. Microbiol., 13.","DOI":"10.3389\/fcimb.2023.1152552"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1080\/14756366.2022.2050224","article-title":"Echinocandins\u2013structure, mechanism of action and use in antifungal therapy","volume":"37","author":"Szymanski","year":"2022","journal-title":"J. Enzyme Inhib. Med. Chem."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"3063","DOI":"10.1093\/jac\/dky280","article-title":"Rezafungin (CD101) demonstrates potent in vitro activity against Aspergillus, including azole-resistant Aspergillus fumigatus isolates and cryptic species","volume":"73","author":"Wiederhold","year":"2018","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"e45","DOI":"10.1016\/j.jinf.2020.08.005","article-title":"COVID-19 associated invasive candidiasis","volume":"82","author":"Mohsin","year":"2021","journal-title":"J. Infect."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1186\/s13756-022-01113-y","article-title":"Microbiologically confirmed infections and antibiotic-resistance in a national surveillance study of hospitalised patients who died with COVID-19, Italy 2020\u20132021","volume":"11","author":"Floridia","year":"2022","journal-title":"Antimicrob. Resist. Infect. Control"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"2001","DOI":"10.1007\/s00134-020-06240-x","article-title":"Invasive candidiasis in critical care: Challenges and future directions","volume":"46","author":"Logan","year":"2020","journal-title":"Intensive Care Med."}],"container-title":["Journal of Fungi"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2309-608X\/10\/6\/397\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T14:51:44Z","timestamp":1760107904000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2309-608X\/10\/6\/397"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5,31]]},"references-count":44,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2024,6]]}},"alternative-id":["jof10060397"],"URL":"https:\/\/doi.org\/10.3390\/jof10060397","relation":{},"ISSN":["2309-608X"],"issn-type":[{"value":"2309-608X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,5,31]]}}}